Is avatrombopag suitable for long-term use?

Whether avatrombopag is suitable for long-term use is a complex issue that requires comprehensive consideration from multiple aspects.

Avatrombopag, as a thrombopoietin receptor agonist, its main function is to stimulate platelet production. This medication is particularly suitable for the treatment of adult patients with thrombocytopenia associated with chronic liver disease, especially before they are scheduled to undergo invasive testing or surgery. However, avatrombopag's mechanism of action also determines its possible risks.

Long-term use of avatrombopag may be associated with thrombotic and thromboembolic complications in patients with chronic liver disease. In addition, its common adverse reactions include fever, abdominal pain, nausea, headache, fatigue and peripheral edema. These side effects make long-term use of avatrombopag a certain health risk.

According to publicly released information, long-term use of avatrombopag is generally not recommended and should only be taken orally for a maximum of 5 days. This is because, in a short period of time, avatrombopag can effectively increase platelet counts to meet the needs of surgery or other invasive examinations. However, long-term use may increase the risk of adverse reactions, and there is no clear long-term therapeutic benefit.

It is important to note that each patient's specific situation may vary. Therefore, when using avatrombopag, you should strictly follow the doctor's instructions and avoid self-medication. Especially for special groups such as pregnant women, the use of this product may cause harm to the fetus, so they should be cautious and consult a professional doctor.

Avatrombopag is not suitable for long-term use. Its short-term use can effectively increase platelet count, but long-term use may bring about a series of adverse reactions and health risks. Therefore, when using avatrombopag, patients should follow the doctor's advice and develop a reasonable medication plan based on their own situation to ensure the safety and effectiveness of the medication. At the same time, for patients who need long-term management of thrombocytopenia, other safer and more effective treatments should be actively explored.